Search the Newsreel

AbbVie Defends Its Turf, But Leaves One Big Question Open

AbbVie (ABBV) is performing strongly, with its stock up and sales growth beating expectations, though its EPS guidance was slightly trimmed due to an acquisition. While the company successfully defended its SKYRIZI sales against new competition, analysts are still concerned about its future pipeline …

AbbVie (ABBV) Stock May Trade At A Premium Despite Cash Flow Upside

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AbbVie stock has delivered a strong 152.2% return over the past 5 years, yet the valuation signals are split, with a Discounted Cash Flow (DCF) intrinsic value …

AbbVie (ABBV) Stock May Be 45% Undervalued On Raised 2026 Outlook

FrontView REIT, Inc. $FVR Shares Bought by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP significantly increased its stake in FrontView REIT, Inc. (NYSE:FVR) during the first quarter, purchasing an additional 63,840 shares to own a total of 83,002 shares valued at $1.28 million. Several other institutional investors also raised their positions in the REIT. …

Viemed Healthcare (NASDAQ:VMD) Lowered to "Buy" Rating by Wall Street Zen

2 Reasons to Like ABBV and 1 to Stay Skeptical

2 Reasons to Like ABBV and 1 to Stay Skeptical AbbVie has followed the market's trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 9.7% to $249.64 per share while the index has gained …

Technical Reactions to SUPV Trends in Macro Strategies

This article analyzes Grupo Supervielle S.a. (NASDAQ: SUPV), noting weak near and mid-term sentiment despite a positive long-term outlook. AI models have generated three trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis highlights a significant 116.5:1 risk-reward …

Riverview Rubber Estates, Berhad Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Die AbbVie-Aktie legt nach starkem Q2-2026-Bericht und angehobener Prognose zu

Can ABBV's Neuroscience Drugs Drive Growth in the Second Half of 2026?

AbbVie's neuroscience franchise experienced strong growth in the first half of 2026, with sales reaching $6.1 billion, driven by key drugs like Vraylar, Ubrelvy, Qulipta, and Botox Therapeutic, and the rapid uptake of Vyalev. The company anticipates further growth from the potential approval of …

Riverview Bancorp Inc 3Q FY2027: Revenue $15.03M, EPS $0.08— 10-Q Summary

Riverview Bancorp Inc (RVSB) reported its 3Q FY2027 results for the quarter ended June 30, 2026, with revenue of $15.03 million and diluted EPS of $0.08, showing a year-over-year improvement. The growth was driven by higher loan income and increased loan balances, particularly in …

Riverview Bancorp (RVSB) lifts Q1 FY2027 profit on stronger net interest income

Manulife Investment Management (US) boosts disclosure of 5.24% Riverview Bancorp (RVSB) stake

Manulife Investment Management (US) LLC, a subsidiary of Manulife Financial Corporation, has disclosed a 5.24% stake in Riverview Bancorp Inc. through an amended Schedule 13G filing. Manulife Investment Management (US) LLC holds sole voting and dispositive power over 1,062,090 shares of Riverview Bancorp common …

Thomasville National Bank Buys Shares of 26,575 AbbVie Inc. $ABBV

Thomasville National Bank acquired a new stake of 26,575 shares in AbbVie Inc., valued at approximately $6.687 million, during the second quarter. AbbVie continues to show strong institutional interest, positive analyst sentiment with a "Moderate Buy" consensus and an average price target of $275.50, …

Riverview Bancorp EVP buys $1,327 in shares

Charmaine Lightheart, EVP/CRDEO at Riverview Bancorp Inc. (NASDAQ:RVSB), recently purchased 250 shares of company stock for $1,327, increasing her direct ownership to 8,766 shares. This insider transaction occurs as analysts forecast profitability for the company this year, with an earnings prediction of $0.28 per …

TeamViewer SE: Konsensus der Analysten und Kursziel | A2YN90 | DE000A2YN900

VinaCapital Vietnam Opportunity Fund boosts treasury stock with latest share buyback

Veolia Environnement (ENXTPA:VIE), What Is Drawing Fresh Attention Now?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Veolia Environnement (ENXTPA:VIE) has drawn fresh attention after a recent pullback, with the stock down about 9% over the past month while still showing a …

Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab?

On July 23, Genmab A/S (NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV) clarified a key clinical setback regarding their jointly developed T-cell engaging bispecific antibody, epcoritamab (DuoBody-CD3xCD20). The Phase 3 EPCORE DLBCL-1 study evaluated epcoritamab monotherapy against investigator's choice of chemoimmunotherapy in transplant-ineligible adults with relapsed/refractory …

Why Avient (AVNT) Is Up 8.1% After Raising 2026 Earnings and Cash Flow Guidance – And What's Next

Navient Corp Keeps Quarterly Dividend at $0.16 per Share, Payable Sept. 18, to Shareholders of Record Sept. 4

Navient Corp (NAVI) has announced that it will maintain its quarterly dividend at $0.16 per share. The dividend is scheduled to be paid on September 18, 2026, to shareholders who are on record as of September 4, 2026. This information was also confirmed by …

Navient declares third quarter common stock dividend

Navient announced that its board of directors has approved a 2026 third quarter dividend of $0.16 per share on the company's common stock. The dividend is scheduled to be paid on September 18, 2026, to shareholders of record as of September 4, 2026. Navient …

Navient declares $0.16 quarterly dividend for Q3 2026

Navient Corporation has announced a quarterly dividend of $0.16 per share on common stock for the third quarter of 2026. The dividend is scheduled to be paid on September 18, 2026, to shareholders of record as of September 4, 2026. Navient specializes in education …

Could AbbVie Inc. (ABBV)’s Post-Humira Transformation Drive the Next Phase of Growth?

AbbVie Inc. (NYSE:ABBV) reported its first-quarter 2026 financial results, delivering worldwide net revenues of $15.002 billion, an increase of 12.4% on a reported basis (10.3% operationally). The company posted GAAP diluted EPS of $0.39 and adjusted diluted EPS of $2.65, which exceeded internal expectations …

Navient shareholders of record will receive $0.16 on Sept. 18

Navient (Nasdaq: NAVI) has declared a third-quarter 2026 common stock dividend of $0.16 per share, approved by its board of directors. The dividend is scheduled to be paid on September 18, 2026, to shareholders who are on record as of the close of business …

(VMD) Risk Channels and Responsive Allocation

This article provides an AI-driven analysis for Viemed Healthcare Inc. (VMD), highlighting weak near and mid-term sentiment but a strong long-term outlook. It outlines three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis emphasizes risk management …

The Sharpest Exchanges From ABBV’s Earnings Call

AVNT Q2 Earnings Top Estimates on Organic Growth, Guidance Up

Avient Corporation (AVNT) reported strong Q2 2026 earnings, surpassing analyst estimates due to robust organic volume growth. The company also raised its full-year 2026 adjusted earnings and EBITDA guidance, anticipating continued growth and improved balance sheet performance. This positive outlook led to a significant …

Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation

Investing.com -- Wolfe Research upgraded two major pharmaceutical companies to Outperform on Thursday, citing stronger growth prospects, attractive valuations and a series of upcoming clinical catalysts. For Biogen, Wolfe raised its rating from Peer Perform and set a $300 price target, arguing that the …

Avient (AVNT) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Investor Relations - Patrick Davis Chairman, President and Chief Executive Officer - Dr. Ashish Khandpur Senior Vice President, Chief Financial Officer - Joe Di Salvo Full Conference Call …

Wolfe Upgrades AbbVie to Outperform From Peer Perform, Price Target is $300

Wolfe has upgraded AbbVie (ABBV) to an "Outperform" rating from "Peer Perform," setting a new price target of $300. This upgrade indicates a more positive outlook on the pharmaceutical company's stock performance. The article also lists recent news and analyst actions related to AbbVie, …

AbbVie Inc. $ABBV Shares Acquired by Mission Wealth Management LP

Mission Wealth Management LP significantly increased its stake in AbbVie Inc. (NYSE:ABBV) by 119.1% in the second quarter, now holding 69,052 shares valued at $17.4 million. This move is part of a broader trend of institutional investors and hedge funds holding 70.23% of AbbVie's …

Grupo Supervielle SA (SUPV) Earnings Forecast: Future EPS & Revenue Growth Estimates